XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX
XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX
OVERLAYS
Fund
Benchmark
3Y · NAV total return · GBP
Franklin Templeton Investment Funds - Franklin Biotechnology Discovery Fund C (acc) USD: holdings, performance and fees
1Y return+66.0%
3Y return+89.9%
5Y return+69.4%
OCF (ongoing charge)2.39%
Top 10 holdings
| Holding | Weight |
|---|---|
| JAZZ PHARMACEUTICALS PUBLIC LIMITED COMPANY | 5.7% |
| AMGEN INC. | 4.3% |
| GILEAD SCIENCES, INC. | 3.9% |
| VERTEX PHARMACEUTICALS INCORPORATED | 3.8% |
| ARGENX SE | 3.8% |
| REGENERON PHARMACEUTICALS INC | 3.2% |
| GUARDANT HEALTH, INC. | 3.1% |
| REVOLUTION MEDICINES INC | 3.1% |
| ASCENDIS PHARMA A/S | 2.9% |
| ORUKA THERAPEUTICS INC | 2.5% |
Top sectors
- Biotechnology76.4%
- Pharmaceuticals17.5%
- Health Care Services3.6%
- Cash & Cash Equivalents2.5%
- Asset Management & Custody Banks0.1%
Top countries
- United States82.5%
- Netherlands4.7%
- Denmark2.9%
- Cash & Cash Equivalents2.5%
- France2.0%
Holdings, sector and country weightings and performance as reported by FE fundinfo. Weightings are a percentage of the portfolio and may not sum to 100.
AI FORECAST · 12-MONTH
Powered by Claude
FREE PREVIEW
Sign up free to unlock the full AI analysis →
UP—
PREMIUM
PREMIUM
Positives
Risks
600 adviser votes
Upgrade for full forecast →
This is an illustrative, model-generated scenario based on stated assumptions. It is not a prediction, a forecast of actual returns, or investment advice. Outcomes may differ materially. Past performance is not a guide to future returns. Capital is at risk.
PORTFOLIO BREAKDOWN